This Article Full Text Full Text (PDF) All Versions of this Article: 34/11/e217    most recent 01.STR.0000099071.46210.3Av1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stöllberger, C. Articles by Singer, D. E. Search for Related Content PubMed PubMed Citation Articles by Stöllberger, C. Articles by Singer, D. E. Pubmed/NCBI databases Medline Plus Health Information Blood Thinners

(Stroke. 2003;34:e217.)
© 2003 American Heart Association, Inc.

Letters to the Editor

Antithrombotic Therapy After Cerebral Hemorrhages

Second Medical Department, Krankenanstalt Rudolfstiftung, Wien, Austria

Josef Finsterer, MD

Neurological Department, Krankenanstalt Rudolfstiftung, Wien, Austria

An extract of the first 250 words of the full text is provided, because this article has no abstract.

To the Editor:

Oral anticoagulation (OAC) generally increases the likelihood of intracerebral hemorrhage (ICH). When there is an indication for OAC in a patient with a history of ICH, the clinician is in the difficult situation of assessing risks and benefits of OAC. In the absence of data from clinical trials, Eckman et al¹ have used a decision-analysis model to compare the expected values of 3 treatment strategies—OAC, aspirin, and no antithrombotic therapy—in patients with ICH and atrial fibrillation (AF).¹ They conclude that all survivors of lobar ICH and most survivors of deep hemispheric ICH with AF should not be offered OAC. Only patients with deep hemispheric ICH at high risk for stroke or embolism or low risk of ICH recurrence might benefit from OAC.¹

Before these recommendations are integrated into clinical practice, several assumptions in the decision-analysis model have to be clarified:

1. The origin of ICH is multifactorial. Some underlying pathologies such as vascular malformations or vasculitis are treatable. For others, no causal treatment is available. Cause and treatment influence the recurrence rate of ICH. Thus, in a patient with ICH and indication for OAC, the ICH origin has to be assessed, as does whether there was any kind of treatment. We miss this kind of evaluation in the model assumptions. Possibly, the assumption is that all secondary causes of ICH like vascular malformations, tumors, hemorrhagic infarcts, trauma, and vasculitis have been definitively excluded. If this is the case, it should be stated.

2. For patients with lobar ICH, . . . [Full Text of this Article]

Mark H. Eckman, MD

Division of General Internal Medicine and, Center for Clinical Effectiveness, University of Cincinnati, Cincinnati, Ohio

Jonathan Rosand, MD; Katherine A. Knudsen, BA Steven M. Greenberg, MD, PhD

Department of Neurology, Massachusetts General Hospital, Boston, Mass

Daniel E. Singer, MD

Department of Medicine, Massachusetts General Hospital, Boston, Mass